Dragonfly, AbbVie expand collaboration to develop new immunotherapies
The extended collaboration is aimed at developing additional drugs for immune-mediated diseases using Dragonfly's unique TriNKET platform
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Apr 22
The extended collaboration is aimed at developing additional drugs for immune-mediated diseases using Dragonfly's unique TriNKET platform
21 Apr 22
The acquisition is said to enhance Samsung Bioepis’ business operations, advance its sales growth, improve operating margin, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Apr 22
With the acquisition, Regeneron will obtain Checkmate’s lead candidate vidutolimod, an investigational, advanced generation CpG-A oligodeoxynucleotide Toll-like receptor…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Apr 22
Labcorp and Xcellbio will jointly work on several projects that will use Xcellbio’s AVATAR incubator system to improve…
19 Apr 22
The British drugmaker’s regulatory submission was based on the Phase 3 ASCEND clinical trial programme, where all the…
19 Apr 22
Nuvaxovid is the first recombinant protein-based Covid-19 vaccine approved in Japan and is based on efficacy and safety…
18 Apr 22
Spikevax was previously authorised by the MHRA for use in adults aged 18 years and above, and for…
18 Apr 22
In the Phase 2/3 clinical trial in 140 children, a booster dose of Comirnaty has increased neutralizing antibodies…
14 Apr 22
Antares’ commercial products and the current autoinjector expertise will help accelerate Halozyme’s approach to drive durable revenue growth…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Apr 22
The proposed acquisition is in line with GSK’s plans to build a strong portfolio of new speciality medicines…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates